MX2023007103A - Moleculas de anticuerpos tetravalentes de union a correceptores fzd y wnt y usos de las mismas. - Google Patents

Moleculas de anticuerpos tetravalentes de union a correceptores fzd y wnt y usos de las mismas.

Info

Publication number
MX2023007103A
MX2023007103A MX2023007103A MX2023007103A MX2023007103A MX 2023007103 A MX2023007103 A MX 2023007103A MX 2023007103 A MX2023007103 A MX 2023007103A MX 2023007103 A MX2023007103 A MX 2023007103A MX 2023007103 A MX2023007103 A MX 2023007103A
Authority
MX
Mexico
Prior art keywords
receptor binding
tetravalent
fzd
wnt
antibody molecules
Prior art date
Application number
MX2023007103A
Other languages
English (en)
Spanish (es)
Inventor
Somasekar Seshagiri
Sachdev Sidhu
Jarrett Adams
Stephane H Angers
Levi Blazer
Original Assignee
Antlera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antlera Therapeutics Inc filed Critical Antlera Therapeutics Inc
Publication of MX2023007103A publication Critical patent/MX2023007103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023007103A 2020-12-18 2021-12-17 Moleculas de anticuerpos tetravalentes de union a correceptores fzd y wnt y usos de las mismas. MX2023007103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127408P 2020-12-18 2020-12-18
PCT/IB2021/061972 WO2022130342A1 (en) 2020-12-18 2021-12-17 Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof

Publications (1)

Publication Number Publication Date
MX2023007103A true MX2023007103A (es) 2023-06-27

Family

ID=82058983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007103A MX2023007103A (es) 2020-12-18 2021-12-17 Moleculas de anticuerpos tetravalentes de union a correceptores fzd y wnt y usos de las mismas.

Country Status (11)

Country Link
US (3) US20250270332A1 (https=)
EP (3) EP4263617A4 (https=)
JP (3) JP7778148B2 (https=)
KR (1) KR20230122077A (https=)
CN (2) CN116917332A (https=)
AU (2) AU2021399278A1 (https=)
CA (2) CA3204321A1 (https=)
CL (2) CL2023001768A1 (https=)
IL (2) IL303344A (https=)
MX (1) MX2023007103A (https=)
WO (2) WO2022130342A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
CN120025448A (zh) * 2019-06-11 2025-05-23 安托拉诊疗公司 多价fzd和wnt结合分子及其用途
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023130055A2 (en) * 2021-12-31 2023-07-06 Surrozen Operating, Inc. Wnt receptor-specific compound and method relating thereto
WO2024007008A2 (en) * 2022-06-30 2024-01-04 The University Of Chicago Cd73 (nt5e) targeting polypeptides
WO2024227103A1 (en) * 2023-04-27 2024-10-31 Surrozen Operating, Inc. Molecules modulating wnt signaling pathways and uses thereof
WO2025019458A2 (en) * 2023-07-14 2025-01-23 The Trustees Of Columbia University In The City Of New York Specific blood retinal barrier defect in glaucoma directs new treatments and clinical tests
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles
US20260092125A1 (en) * 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof
WO2026055312A1 (en) * 2024-09-06 2026-03-12 Merck Sharp & Dohme Llc Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
EP2804629A1 (en) 2012-01-18 2014-11-26 Genentech, Inc. Anti-lrp5 antibodies and methods of use
DE102012202081A1 (de) 2012-02-13 2013-08-14 Osram Gmbh Glühfaden für elektrische lampen und elektrische lampe sowie herstellungsverfahren für einen glühfaden
AU2014246658B2 (en) 2013-04-03 2018-10-04 Peter Maccallum Cancer Institute Antibodies against human RYK and uses therefor
US9237411B2 (en) 2013-07-25 2016-01-12 Elwha Llc Systems and methods for providing one or more functionalities to a wearable computing device with directional antenna
EP3033356B1 (en) 2013-08-14 2020-01-15 Sachdev Sidhu Antibodies against frizzled proteins and methods of use thereof
JP6865688B2 (ja) 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
US10919968B2 (en) 2016-01-29 2021-02-16 Modmab Therapeutics Corporation Frizzled5 protein-binding agents
WO2018026942A1 (en) 2016-08-02 2018-02-08 Merrimack Pharmaceuticals, Inc. Heteromeric polypeptides
US11039659B2 (en) 2017-09-07 2021-06-22 Nike, Inc. Sole structure for article of footwear
US20210032352A1 (en) 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
CA3104526A1 (en) * 2018-07-05 2020-01-09 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof
US10671121B2 (en) 2018-09-14 2020-06-02 Apple Inc. Magnetic layout in electronic devices and accessory devices for electronic devices
CN120025448A (zh) * 2019-06-11 2025-05-23 安托拉诊疗公司 多价fzd和wnt结合分子及其用途

Also Published As

Publication number Publication date
CA3204322A1 (en) 2022-06-23
JP2026041774A (ja) 2026-03-10
JP2023554500A (ja) 2023-12-27
US20240132600A1 (en) 2024-04-25
WO2022130341A1 (en) 2022-06-23
EP4543921A2 (en) 2025-04-30
WO2022130342A4 (en) 2022-08-11
US20240228631A9 (en) 2024-07-11
EP4263618A4 (en) 2024-11-20
US20230118983A1 (en) 2023-04-20
AU2021404080A1 (en) 2023-06-29
CA3204321A1 (en) 2022-06-23
EP4263617A4 (en) 2025-01-01
EP4263618A1 (en) 2023-10-25
EP4263617A1 (en) 2023-10-25
CL2025001491A1 (es) 2025-08-22
CL2023001768A1 (es) 2024-01-12
CN116917332A (zh) 2023-10-20
JP7778148B2 (ja) 2025-12-01
IL303344A (en) 2023-08-01
CN116964102A (zh) 2023-10-27
WO2022130342A1 (en) 2022-06-23
IL303342A (en) 2023-08-01
AU2021399278A1 (en) 2023-06-29
KR20230122077A (ko) 2023-08-22
JP2024500839A (ja) 2024-01-10
US20250270332A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
MX2023007103A (es) Moleculas de anticuerpos tetravalentes de union a correceptores fzd y wnt y usos de las mismas.
AU2021399278A9 (en) Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
AU2021404080A9 (en) Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
CL2021002370A1 (es) Mezclado controlado de fracciones de transmezcla en corrientes de hidrocarburo definidas
CO2019009076A2 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
EP3871217A4 (en) METHOD AND DEVICE FOR ADJUSTING AUDIO PLAYBACK SETTINGS BASED ON ANALYSIS OF AUDIO CHARACTERISTICS
MA45517B1 (fr) Molécules de liaison inhibant la croissance de cancer
BR112018013677A2 (pt) proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
CO2018000967A2 (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
BR112018013911A2 (pt) proteínas de fusão de ligação a ox40 multivalentes e multiespecíficas
CL2019003286A1 (es) Ensayos de diagnóstico para detectar, cuantificar y/o rastrear microbios y otros analitos.
MX2021015439A (es) Moleculas multivalentes de union a fzd y wnt y usos de las mismas.
NZ724815A (en) Humanized antibodies that bind lgr5
MX2010004726A (es) Antigeno asociado con artritis reumatoide.
BR112018067851A2 (pt) composições e métodos para o tratamento de artrite reumatoide
BR112015013771A8 (pt) preditividade por biomarcadores da resposta a tratamentos com ativadores do receptor alfa 7 nicotínico de acetilcolina
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
AR073140A1 (es) Anticuerpos anti-il-23r disenados
MX2022004022A (es) Combinaciones de moduladores alostericos positivos del receptor de gaba-a y antagonistas de nmda, moduladores alostericos negativos de nmda o agonistas parciales de nmda.
EP3804850A4 (en) HYDROCARBON REFORMING CATALYST AND HYDROCARBON REFORMING DEVICE
WO2023250402A3 (en) Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
CL2023003151A1 (es) Anticuerpos anti-notch2 y métodos de uso
MX2021000786A (es) Receptor para supresor de ig del dominio v de activación de células t (vista).
WO2022078985A3 (en) Microbiome signature for the charcatrization of skin types
EP3887715A4 (en) OPTICAL ARRANGEMENT, LIGHTING AND/OR SIGNALING DEVICE AND VEHICLE